Five sessions of hyperbaric oxygen for critically ill patients with COVID-19-induced ARDS: A randomised, open label, phase II trial.
Anders KjellbergJohan DouglasMichael T PawlikAdrian HasslerSarah Al-EzerjawiEmil BoströmLina Abdel-HalimLovisa LiwenborgAnna-Dora Jonasdottir-NjåstadJan KowalskiSergiu-Bogdan CatrinaKenny A Rodriguez-WallbergPeter LindholmPublished in: Respiratory medicine (2024)
HBOT did not reduce ICU admission or mortality in patients with COVID-19-induced ARDS. The trial cannot conclude definitive benefits or harms. Treating COVID-19-induced ARDS with HBOT is feasible with a favourable harms profile.
Keyphrases
- open label
- high glucose
- clinical trial
- acute respiratory distress syndrome
- diabetic rats
- mechanical ventilation
- extracorporeal membrane oxygenation
- coronavirus disease
- phase iii
- sars cov
- intensive care unit
- phase ii
- drug induced
- squamous cell carcinoma
- type diabetes
- cardiovascular disease
- endothelial cells
- oxidative stress
- cardiovascular events
- radiation therapy
- stress induced